Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH ALHALEL

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1700830353
CMS profile
32241
Location
MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$775.96

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $775.96 21

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH ALHALEL

NPI 1700830353 · CMS profile ID 32241

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700830353?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700830353?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700830353?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1700830353?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $775.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $7.6411/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118409 CMS
AbbVie Inc. $32.8408/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118407 CMS
AbbVie Inc. $20.9708/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118405 CMS
Ardelyx, Inc. $83.7207/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052934379 CMS
Rhythm Pharmaceuticals, Inc. $124.9907/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051221325 CMS
AbbVie Inc. $24.4607/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118403 CMS
AbbVie Inc. $19.8507/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118401 CMS
AbbVie Inc. $17.3606/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118399 CMS
AbbVie Inc. $123.0506/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118397 CMS
AbbVie Inc. $2.0906/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118395 CMS
AbbVie Inc. $33.5806/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118393 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $124.9905/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057340095 CMS
AbbVie Inc. $4.5205/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118391 CMS
Ironwood Pharmaceuticals, Inc $21.7004/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045528007 CMS
Celgene Corporation $16.2803/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015816743 CMS
AbbVie Inc. $18.3703/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118389 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.9003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057426041 CMS
AbbVie Inc. $17.9102/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118387 CMS
Celgene Corporation $18.3001/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015816699 CMS
NESTLE HEALTHCARE NUTRITION INC. $19.9501/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012469693 CMS
AbbVie Inc. $26.4901/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996118385 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $749.94 37
PY2020 $420.45 27
PY2021 $703.45 46
PY2022 $1,041.54 42
PY2023 $775.96 21
PY2024 $1,310.53 38
PY2025 $447.58 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $352,790.88 227
PY2024 Principal investigator $269,533.46 68
PY2023 Principal investigator $335,027.89 61
PY2022 Recipient $1.00 1
PY2022 Principal investigator $35,164.94 37
PY2021 Recipient $938.46 1
PY2021 Principal investigator $34,998.93 15
PY2020 Principal investigator $98,605.96 19
PY2019 Recipient $9,135.15 2
PY2019 Principal investigator $18,309.40 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 12/30/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949773479
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 12/30/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949773481
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 11/30/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949774185
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 11/30/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949774271
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 10/31/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949773483
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 10/31/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949773833
Principal investigator 1 Eli Lilly and Company $70.00 10/15/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC RESEARCH CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 917818125
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 10/12/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF PVP001, PVP002, AND PVP003 IN HEALTHY ADULTS AND PVP001 AND PVP002 IN ADULTS WITH CELIAC DISEASE No dispute reported 06/30/2026 937175713
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 10/12/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF PVP001, PVP002, AND PVP003 IN HEALTHY ADULTS AND PVP001 AND PVP002 IN ADULTS WITH CELIAC DISEASE No dispute reported 06/30/2026 937175715
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 10/12/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF PVP001, PVP002, AND PVP003 IN HEALTHY ADULTS AND PVP001 AND PVP002 IN ADULTS WITH CELIAC DISEASE No dispute reported 06/30/2026 937175717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/12/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF PVP001, PVP002, AND PVP003 IN HEALTHY ADULTS AND PVP001 AND PVP002 IN ADULTS WITH CELIAC DISEASE No dispute reported 06/30/2026 937175719
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 10/12/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF PVP001, PVP002, AND PVP003 IN HEALTHY ADULTS AND PVP001 AND PVP002 IN ADULTS WITH CELIAC DISEASE No dispute reported 06/30/2026 937175721
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 10/05/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 937175305
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,400.00 10/05/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 937175307
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 10/05/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 937175309
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,519.00 10/05/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 937175311
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 10/05/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 937175315
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 10/05/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 937175317
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/05/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 937175319
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/05/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 937175321
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 09/30/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949764639
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 09/30/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949765191
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 08/31/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949764429
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 08/31/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949764641
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 07/30/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949764425
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 07/30/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949764427
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 06/30/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949765133
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 06/30/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949765185
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 05/31/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949765131
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 05/31/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949765137
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $500.00 05/20/2022 Non-covered Recipient Entity
Biopharma Informatic LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949765189
Principal investigator 1 Eli Lilly and Company $11,509.00 05/03/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 917821827
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 04/29/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949764977
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 04/29/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949765135
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 03/31/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949764979
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 03/31/2022 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 949765187
Recipient Eli Lilly and Company $1.00 01/26/2022 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 917814633
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,306.94 01/25/2022 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC DBA RESEARCH CONSULTANTS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 937162361